Patients with Dermatologists More Likely to Catch Melanoma Early

Published Online: Wednesday, April 16, 2014
Follow Pharmacy_Times:
Patients with an established dermatologist may be more likely to detect early-stage melanoma than those without, the results of a study indicate.

The recent study, published online on March 14, 2014, in the Journal of the American Academy of Dermatology, analyzed associations between previous dermatologic examinations, the amount of time since the last examination, and the wait time for a dermatology appointment with melanoma invasiveness and depth among melanoma patients at an academic dermatology department.

Patients with an established dermatologist were more likely to receive a diagnosis of melanoma in situ and to have thinner invasive melanoma compared with patients without a dermatologist. These trends were only observed for patients with self-detected, not dermatologist-detected, melanoma. Self-detected cases of melanoma accounted for 51% of all cases, 41.7% of in situ melanoma cases, and 62.4% of invasive cases of melanoma. Among self-detected melanoma cases, 59% of patients with an established dermatologist were diagnosed with in situ melanoma, compared with 37% of patients without a dermatologist.

“Education obtained at the dermatology appointment may improve early self-detection of melanoma, and having an established dermatologist may facilitate earlier evaluation of concerning lesions,” the study authors conclude.

Related Articles
Whereas previous research indicated that coffee consumption may protect against nonmelanoma skin cancers, a recent study suggested that drinking coffee could decrease a patient’s risk of developing malignant melanoma as well.
Community pharmacists play a significant role in helping patients to maintain the health of their skin.
The FDA has approved Merck’s Keytruda injection for the treatment of patients with unresectable or metastatic melanoma and disease progression following administration of ipilimumab and, if positive for the BRAF V600 mutation, a BRAF inhibitor.
Keytruda, manufactured by Merck, is indicated for treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and a BRAF inhibitor.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$